title: [Estimated methods of predicting risk of analgetic interstitial renal disease].
abstract: OBJECTIVE
  Screening of renal pathology and investigation of its dependence on intake of metamisol, the risk of nephritis associated with metamisol.
  
  
  METHODS
  The study included 1446 inpatients (mean age 49.63 +/- 0.43 years, 690 males--48%, 756 females--52%). Analysis of the urine, tests for urea, blood creatinine, estimation of glomerular filtration rate were made. Metamisol doses and duration of analgetic treatment were controlled in 658 patients. Statistical processing was made with Statistica 6.0 soft.
  
  
  RESULTS
  Of 1446 examinees, 346 (23.9%) patients took analgetics. Out of 98 patients treated with metamisol, 34 (34.7%) had pathology of urinary sediment, 18 (18.4%) had suppression of renal function (RF) while in patients untreated with analgetics this percentage was 7.4 and 16.1%, respectively, p < 0.05. In intake of metamisol from 0.5 to 5.0 kg and more changes in urine analysis parameters and regress of RF were more prominent than in intake up to 0.5 kg (p < 0.05). Application of nonlinear logistic regression analysis provided equations of logistic regression making it possible to assess probability of changes in urine analysis and renal function decline depending on the drug dose and duration of its intake.
  
  
  CONCLUSIONS
  Inpatients often take analgetic drugs, especially metamisol. Its high doses are associated with risk of renal function decline and pathology of urinary sediment. Equations of calculation of renal affection risk in administration of metamisol are presented.
authors.forename: M M
authors.initials: MM
authors.lastname: Batiushin
authors.forename: O V
authors.initials: OV
authors.lastname: Dmitrieva
authors.forename: V P
authors.initials: VP
authors.lastname: Terent'ev
authors.forename: K S
authors.initials: KS
authors.lastname: Davidenko
mesh_terms: D000700:Analgesics / Q000009:adverse effects* / Q000493:pharmacokinetics; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000493:pharmacokinetics; D004177:Dipyrone / Q000009:adverse effects* / Q000493:pharmacokinetics; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009395:Nephritis, Interstitial / Q000139:chemically induced* / Q000503:physiopathology / Q000652:urine; D011379:Prognosis; D012307:Risk Factors
chemical_list: D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004177:Dipyrone